Short Interest in PainReform Ltd. (NASDAQ:PRFX) Declines By 81.7%

PainReform Ltd. (NASDAQ:PRFX) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 57,440 shares, a decrease of 81.7% from the May 31st total of 313,070 shares. Based on an average daily trading volume, of 4,968,100 shares, the short-interest ratio is presently 0.0 days. Currently, 10.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, PainReform presently has a consensus rating of “Sell”.

PainReform Price Performance

PainReform stock opened at $1.60 on Friday. The business has a 50 day simple moving average of $1.86 and a 200-day simple moving average of $2.83. PainReform has a 12 month low of $1.28 and a 12 month high of $17.95. The stock has a market capitalization of $1.39 million, a PE ratio of -0.00 and a beta of 0.98.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($1.01) earnings per share for the quarter.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.